NK-92 DNAM-1

NK-92 DNAM-1 is an **engineered natural killer (NK) cell therapy** based on the established NK-92 cell line, genetically modified to overexpress DNAM-1 (CD226), an activating receptor. The modification aims to improve NK cell recognition and killing of cancer cells, specifically by enhancing cytotoxicity toward tumor cells that express the DNAM-1 ligands CD112 and CD155. DNAM-1 signals through an ITT-like motif, leading to recruitment of intracellular signaling effectors and robust activation of cytotoxic and cytokine production pathways. NK-92 DNAM-1 demonstrates significantly greater **antitumor activity** against acute myeloid leukemia (AML) and various solid tumor cell lines in both in vitro and in vivo (xenograft) models compared to the parental NK-92 cells, especially when tumor targets express high levels of CD112/CD155. This therapy is in preclinical and early translational development stage, with research primarily focused on hematologic malignancies such as AML, and in solid tumors such as sarcoma[1][2][3][4].

Other names

NK-92 DNAM-1NK92 DNAM-1NK 92 DNAM-1